Nuvation Bio's Safusidenib Posts Durable Responses in IDH1 Glioma
Nuvation Bio reported updated Phase 2 data for safusidenib in IDH1-mutant glioma, with a 51.9% response rate and a 79.1% three-year progression-free rate.
Editorial Read →
Small-cap biotech intelligence
The catalysts moving small-cap biotech — every trading day.
Daily commentary on FDA decisions, trial readouts, financings and the stocks reacting to them — plus live market, filings and news trackers.
The Briefing
Charts by TradingView
Live Trackers
Full market view →Market Pulse
Sector heat & sentiment
silvergoldcopperlithiumcobaltnickel
Silver and copper are leading at the CSE/TSX-V open with spot prices up 2.17% and 2.33% respectively, supporting early buying in precious- and base-me…
News Wire
Latest headlines
- Canadian Copper Inc. Announces Closing of $44M Project Financing with OR Royalties Inc.
- Rockland Reports 79.9 G/T Gold Near Surface And Confirms New Gold Zone 1.1 Kilometres From The Historic Cole Mine, Red Lake, Ontario
- Azimut Exploration Reports High-Grade Lithium Pegmatite Drilling Results at Wabamisk East, Including 1.87% Li2O over 36.30 metres and 2.20% Li2O over 23.05 metres
- Q2 Metals Commences Summer Drill Program and Advances Toward PEA on the Cisco Lithium Project in Quebec, Canada
Filings Watch
Recent filings
- Azimut Exploration Inc. — Private Placement, July 20, 2026
- Abasca Resources Inc. — Private Placement, July 20, 2026
- Greenridge Exploration Inc. — Private Placement, July 20, 2026
Latest Articles
All articles →REGENXBIO's Gene Therapy Shows Five-Year Durability in Retinal Disease
REGENXBIO reported long-term data showing its AbbVie-partnered gene therapy sura-vec preserved vision and cut injection burden through five years in wet AMD.
Editorial Read →
4DMT's One-Shot Eye Therapy Holds Up at Two Years in Wet AMD
4DMT presented two-year Phase 2b PRISM data showing its gene therapy 4D-150 cut anti-VEGF treatment burden by 78% while maintaining vision in wet AMD.
Editorial Read →
Trevi Therapeutics Jumps as GSK Exits the Chronic Cough Race
Trevi Therapeutics shares climbed nearly 10% after GSK abandoned its chronic cough candidate camlipixant, removing a leading competitor to Trevi's Haduvio.
Editorial Read →
Jasper Therapeutics Reinvents Itself With Kira Merger and $132M Raise
Jasper Therapeutics announced an all-stock merger with Kira Pharmaceuticals alongside a roughly $132 million private placement, reshaping its pipeline and balance sheet.
Editorial Read →
Intensity Therapeutics Restarts Its INVINCIBLE-4 Breast Cancer Trial
Intensity Therapeutics resumed dosing of INT230-6 in its Phase 2 presurgical triple-negative breast cancer trial under an amended, lower-dose protocol.
Editorial Read →
Celcuity Lands Its First FDA Approval With REVTORPYK
Celcuity won FDA approval for REVTORPYK in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer, marking the company's first commercial product.
Editorial Read →
Q32 Bio's Bempikibart Regrows Hair in Tough Alopecia Cases
Q32 Bio reported 36-week Phase 2a data showing its antibody bempikibart drove meaningful hair regrowth in patients with severe alopecia areata.
Editorial Read →
Cue Biopharma Lines Up $50M Private Placement Led by Cormorant
Cue Biopharma announced a $50 million private placement led by Cormorant Asset Management to fund clinical development, expected to close on or about July 13, 2026.
Editorial Read →
Forte Biosciences Posts Positive Phase 1b Vitiligo Data for FB102
Forte Biosciences reported that its FB102 candidate met the primary endpoint in a Phase 1b vitiligo study, showing a statistically significant improvement over placebo at week 24.
Editorial Read →
Arcutis Biotherapeutics: FDA Accepts ZORYVE Filing for Infant Eczema
The FDA accepted Arcutis Biotherapeutics' supplemental application to expand ZORYVE cream into infants with atopic dermatitis, with a decision targeted for February 2027.
Editorial Read →
MeiraGTx Secures Up to $400M From Oberland to Fund Gene Therapies
MeiraGTx entered a largely non-dilutive financing of up to $400 million with Oberland Capital to support its late-stage retinitis pigmentosa and xerostomia gene therapy programs.
Editorial Read →
Never miss a catalyst.
One concise briefing. The movers, the filings, the FDA calendar.